ViewRay Inc. (VRAY) gains 2.45% for July 21

Equities Staff  |

ViewRay Inc. (NASDAQ: VRAY) shares gained 2.45%, or $0.16 per share, to close Wednesday at $6.68. After opening the day at $6.62, shares of ViewRay fluctuated between $6.70 and $6.50. 655,166 shares traded hands a decrease from their 30 day average of 1,429,731. Wednesday's activity brought ViewRay’s market cap to $1,080,424,877.

ViewRay is headquartered in Oakwood Village, Ohio..

About ViewRay Inc.

ViewRay, Inc., designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Visit ViewRay Inc.’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on ViewRay Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: ViewRay Inc.’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content